AlphaLiquid®100 is an innovative, cutting-edge liquid biopsy test that empowers personalized cancer care by detecting biomarkers across 118 cancer-related genesthrough just one blood draw. This non-invasive, highly advanced test is essential for predicting a patient's response or resistance to targeted therapies.

Integrated seamlessly into the cancer treatment journey, AlphaLiquid®100 enables real-time monitoring of treatment effectiveness. By identifying emerging resistance biomarkers early, it supports timely adjustments to therapeutic strategies - ensuring a more personalized, proactive, and adaptive approach to cancer management.